This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UBX UNITY Biotechnology (UBX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About UNITY Biotechnology Stock (NASDAQ:UBX) Get UNITY Biotechnology alerts:Sign Up Key Stats Today's Range$0.20▼$0.3250-Day Range$0.18▼$0.8852-Week Range$0.20▼$3.10Volume3.73 million shsAverage Volume284,137 shsMarket Capitalization$3.08 millionP/E RatioN/ADividend YieldN/APrice Target$2.33Consensus RatingHold Company Overview Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Read More UNITY Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreUBX MarketRank™: UNITY Biotechnology scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingUNITY Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Upside PotentialUNITY Biotechnology has a consensus price target of $2.33, representing about 1,203.5% upside from its current price of $0.18.Amount of Analyst CoverageUNITY Biotechnology has received no research coverage in the past 90 days.Read more about UNITY Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for UNITY Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUNITY Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for UBX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUNITY Biotechnology does not currently pay a dividend.Dividend GrowthUNITY Biotechnology does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.60 Short InterestThere is no current short interest data available for UBX. News and Social MediaN/ANews SentimentN/A Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, UNITY Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of UNITY Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 29.49% of the stock of UNITY Biotechnology is held by institutions.Read more about UNITY Biotechnology's insider trading history. Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UBX Stock News HeadlinesUnity Stock Crashes Nearly 50% After Nasdaq Delisting NoticeJune 30, 2025 | finance.yahoo.comUnity Biotechnology stock plunges after Nasdaq delisting noticeJune 30, 2025 | za.investing.comAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says the real opportunity is in a little-known strategy that has historically outpaced gold’s rallies many times over — including one past run where investors saw gains of more than 26,000%.October 4 at 2:00 AM | Weiss Ratings (Ad)Unity Biotechnology Inc News (UBX) - Investing.comJune 26, 2025 | investing.comUBX Unity Biotechnology, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comHC Wainwright & Co. Downgrades Unity Biotechnology (UBX)May 28, 2025 | msn.comUnity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho SecuritiesMay 18, 2025 | theglobeandmail.comBay Area biotech company Unity lays off every single worker, including CEOMay 6, 2025 | msn.comSee More Headlines UBX Stock Analysis - Frequently Asked Questions How were UNITY Biotechnology's earnings last quarter? UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its earnings results on Tuesday, April, 22nd. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). When did UNITY Biotechnology's stock split? UNITY Biotechnology's stock reverse split on the morning of Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did UNITY Biotechnology IPO? UNITY Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager. What other stocks do shareholders of UNITY Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK). Company Calendar Last Earnings4/22/2025Today10/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UBX CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees60Year Founded2009Price Target and Rating Average Price Target for UNITY Biotechnology$2.33 High Price Target$4.00 Low Price Target$1.00 Potential Upside/Downside+1,203.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.99 million Net MarginsN/A Pretax MarginN/A Return on Equity-246.82% Return on Assets-58.81% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book0.46Miscellaneous Outstanding Shares17,212,000Free Float16,214,000Market Cap$3.08 million OptionableOptionable Beta0.92 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:UBX) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UNITY Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share UNITY Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.